[{"orgOrder":0,"company":"Second Affiliated Hospital, Zhejiang University","sponsor":"Credit Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tizanidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase III","graph3":"Second Affiliated Hospital, Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Second Affiliated Hospital, Zhejiang University \/ Credit Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Second Affiliated Hospital, Zhejiang University \/ Credit Pharmaceutical"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tizanidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Urology","graph2":"Phase III","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Endeavor Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Endeavor Health \/ Inapplicable"},{"orgOrder":0,"company":"Delpor","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Tizanidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Delpor","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Implant","sponsorNew":"Delpor \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Delpor \/ National Institutes of Health"}]

Find Clinical Drug Pipeline Developments & Deals for Tizanidine Hydrochloride

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Access all COS suppliers
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Tizanidine Hydrochloride

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

38 API Suppliers, 13 USDMF, 1 CEP/COS, 6 JDMF, 5 EU WC, 3 KDMF, 8 NDC API, 21 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

11 Drugs in Development

11 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

117 FDF Dossiers, 75 FDA Orange Book, 13 Europe, 2 Canada, 27 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 4MG BASE, CAPSULE;ORAL - EQ 2MG BASE, CAPSULE;ORAL - EQ 4MG BASE, CAPSULE;ORAL - EQ 6MG BASE

RELATED EXCIPIENT COMPANIES

2 Evonik, 4 SPI Pharma, 10 DKSH, 4 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 2 Kirsch Pharma, 4 ACG Worldwide, 1 Actylis, 1 Aeon Procare, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 10 BASF, 10 Corel Pharma Chem, 6 DFE Pharma, 3 Doshion Polyscience, 1 Finar, 6 Gangwal Chemicals, 4 Ideal Cures, 3 Ingredion Pharma Solutions, 24 Kerry, 2 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 8 Microlex e.U, 1 Nitika Pharmaceutical Specialities, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 4 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 18 Roquette, 8 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 10 Sigachi Industries, 2 Silverline Chemicals, 2 The Dow Chemical Company, 1 Valens Pharmachem, 2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

45 Coating Systems & Additives, 42 Fillers, Diluents & Binders, 28 Direct Compression, 25 Granulation, 22 Thickeners and Stabilizers, 17 Controlled & Modified Release, 17 Disintegrants & Superdisintegrants, 13 Taste Masking, 10 Film Formers & Plasticizers, 10 Co-Processed Excipients, 9 Lubricants & Glidants, 9 Empty Capsules, 8 Chewable & Orodispersible Aids, 5 Coloring Agents, 5 Emulsifying Agents, 5 Topical, 5 Rheology Modifiers, 4 Vegetarian Capsules, 4 API Stability Enhancers, 4 Solubilizers, 3 Parenteral, 1 Surfactant & Foaming Agents

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 24 News #PharmaBuzz

GLOBAL SALES INFORMATION

20 US Medicaid Prescriptions, 19 Regulatory FDF Prices

MARKET PLACE

10 APIs, 2 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents

2 US Patents

REF. STANDARDS & IMPURITIES

1 Others

1 Others

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Dr. Reddy's Laboratories

India

CPhI WW Frankfurt

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Lead Product(s) : Tizanidine Hydrochloride

Therapeutic Area : Undisclosed

Study Phase : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Bioequivalence Study of Tizanidine HCl Tablets 4 mg of Dr.Reddys Under Fasting Conditions

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

June 17, 2010

Lead Product(s) : Tizanidine Hydrochloride

Therapeutic Area : Undisclosed

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Dr Reddy Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

Dr. Reddy's Laboratories

India

CPhI WW Frankfurt

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Lead Product(s) : Tizanidine Hydrochloride

Therapeutic Area : Undisclosed

Study Phase : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Bioequivalence Study of Tizanidine HCl 4mg Tablets of Dr.Reddy's Under Fed Conditions

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

February 10, 2010

Lead Product(s) : Tizanidine Hydrochloride

Therapeutic Area : Undisclosed

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Dr Reddy Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

03

Endeavor Health

Country

Peptide Process CMC

Not Confirmed

04

Second Affiliated Hospital, Zhejiang University

Country

Peptide Process CMC

Not Confirmed

05

Delpor

U.S.A

Peptide Process CMC

Not Confirmed

06

F. Hoffmann-La Roche

Switzerland

Peptide Process CMC

Not Confirmed

07

Acorda Therapeutics

U.S.A

Peptide Process CMC

Not Confirmed

08

Acorda Therapeutics

U.S.A

Peptide Process CMC

Not Confirmed